Page 32 - Nsclc News Today

Treatment with repotrectinib continued to produce high and durable responses with a manageable safety profile in patients with ROS1-positive locally advanced or metastatic non–small cell lung cancer who were naïve to a TKI or previously treated with 1 TKI and no chemotherapy.

The natural killer T-cell agonist IMM60 may overcome resistance to PD-1 inhibitors when combined with immunotherapy in patients with melanoma and non–small cell lung cancer.

Coverage of research presented by Strategic Alliance Partners: OneOncology, Florida Cancer Specialists & Research Institute, and The US Oncology Network.

Karen L. Reckamp, MD, MS, discusses current and emerging antibody-drug conjugates in lung cancer in addition to highlighting the development of patritumab deruxtecan and telisotuzumab vedotin.

Pasi A. Jänne, MD, PhD, discusses key trials evaluating the efficacy of single-agent osimertinib in patients with metastatic EGFR-mutated non–small cell lung cancer.

Second-line treatments for small cell lung cancer are effective, but the outcomes are modest, explained Tom Stinchcombe, MD, medical oncologist, Duke Cancer Institute.

In an interview with Targeted Oncology, Sagun Shrestha, MD, evaluated new developments and clinical trials for patients with extensive-stage small cell lung cancer.

Expert oncologists discuss important dosing considerations and treatment management strategies for lurbinectedin and other second-line therapy approaches in small-cell lung cancer.

Coverage from the Institute for Value-Based Medicine event in Atlanta, held in partnership with Winship Cancer Institute of Emory University.

Patients who underwent plasma ctDNA testing started therapy for advanced NSCLC earlier than those who underwent only tissue biopsy, but "plasma first does not mean plasma only," the authors say.